PHARMA 310505: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
PHARMA 310505
Largest movements
- Cash +€402,279
up €402,279 (+5,865%), from €6,859 to €409,138
mainly Contributions, distributions and other (+€300,000) and Debts after one year (+€255,683)
- Stocks and contracts +€237,632
new in 2025: €237,632
- Receivables within one year +€179,010
up €179,010 (+147%), from €121,520 to €300,530
of which Other amounts receivable: +€178,480
- Intangible fixed assets -€71,000
down €71,000 (-50.0%), from €142,000 to €71,000
- Tangible fixed assets +€59,993
new in 2025: €59,993
- Contributions +€300,000
up €300,000 (+1,613%), from €18,600 to €318,600
- Debts after one year +€255,683
up €255,683 (+254%), from €100,583 to €356,266
- Other debts +€146,286
up €146,286 (+1,892%), from €7,733 to €154,019
- Current portion of long-term debt +€73,337
up €73,337 (+95.3%), from €76,917 to €150,254
- Reserves +€28,950
up €28,950 (+44.2%), from €65,521 to €94,471
- Gross operating margin +€2,410
up €2,410 (+2.2%), from €108,049 to €110,459
- Financial charges -€2,023
down €2,023 (-41.4%), from €4,882 to €2,859
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €270,791 | €1,078,496 | +€807,706 | +298% |
| Fixed assets | 21/28 | €142,000 | €130,993 | -€11,007 | -7.8% |
| Intangible fixed assets | 21 | €142,000 | €71,000 | -€71,000 | -50.0% |
| Tangible fixed assets | 22/27 | - | €59,993 | +€59,993 | |
| Plant, machinery and equipment | 23 | - | €59,993 | +€59,993 | |
| Current assets | 29/58 | €128,791 | €947,504 | +€818,712 | +636% |
| Stocks and contracts in progress | 3 | - | €237,632 | +€237,632 | |
| Stocks | 30/36 | - | €237,632 | +€237,632 | |
| Amounts receivable within one year | 40/41 | €121,520 | €300,530 | +€179,010 | +147% |
| Trade receivables | 40 | - | €530 | +€530 | |
| Other amounts receivable | 41 | €121,520 | €300,000 | +€178,480 | +147% |
| Cash at bank and in hand | 54/58 | €6,859 | €409,138 | +€402,279 | +5,865% |
| Deferred charges and accrued income | 490/1 | €413 | €204 | -€209 | -50.5% |
| Total equity and liabilities | 10/49 | €270,791 | €1,078,496 | +€807,706 | +298% |
| Equity | 10/15 | €84,121 | €413,071 | +€328,950 | +391% |
| Contributions | 10/11 | €18,600 | €318,600 | +€300,000 | +1,613% |
| Reserves | 13 | €65,521 | €94,471 | +€28,950 | +44.2% |
| Distributable reserves | 133 | €65,521 | €94,471 | +€28,950 | +44.2% |
| Amounts payable | 17/49 | €186,670 | €665,425 | +€478,756 | +256% |
| Amounts payable after more than one year | 17 | €100,583 | €356,266 | +€255,683 | +254% |
| Financial debts | 170/4 | €100,583 | €356,266 | +€255,683 | +254% |
| Amounts payable within one year | 42/48 | €85,828 | €308,949 | +€223,121 | +260% |
| Current portion of amounts payable after more than one year | 42 | €76,917 | €150,254 | +€73,337 | +95.3% |
| Trade debts | 44 | €327 | €1,588 | +€1,261 | +386% |
| Suppliers | 440/4 | €327 | €1,588 | +€1,261 | +386% |
| Taxes, remuneration and social security | 45 | €851 | €3,088 | +€2,237 | +263% |
| Taxes | 450/3 | €851 | €3,088 | +€2,237 | +263% |
| Other amounts payable | 47/48 | €7,733 | €154,019 | +€146,286 | +1,892% |
| Accrued charges and deferred income | 492/3 | €258 | €210 | -€48 | -18.6% |
| Non-recurring operating income | 76A | - | €2,715 | +€2,715 | |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €71,000 | €71,007 | +€7 | 0.0% |
| Other operating charges | 640/8 | €1,133 | €1,827 | +€693 | +61.2% |
| Gross operating margin | 9900 | €108,049 | €110,459 | +€2,410 | +2.2% |
| Operating profit (loss) | 9901 | €35,915 | €37,625 | +€1,710 | +4.8% |
| Financial income | 75/76B | €3,846 | €4,272 | +€426 | +11.1% |
| Recurring financial income | 75 | €3,846 | €4,272 | +€426 | +11.1% |
| Financial charges | 65/66B | €4,882 | €2,859 | -€2,023 | -41.4% |
| Recurring financial charges | 65 | €4,882 | €2,859 | -€2,023 | -41.4% |
| Profit (loss) for the period before taxes | 9903 | €34,879 | €39,038 | +€4,159 | +11.9% |
| Income taxes | 67/77 | €9,014 | €10,088 | +€1,074 | +11.9% |
| Profit (loss) for the period | 9904 | €25,865 | €28,950 | +€3,084 | +11.9% |
| Profit (loss) for the period to be appropriated | 9905 | €25,865 | €28,950 | +€3,084 | +11.9% |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 29 October 2026 via checked.be.